홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

트라이헵타노인

Triheptanoin

HCID 69286
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
620-67-7
표준 SMILES
CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC
InChIKey
PJHKBYALYHRYSK-UHFFFAOYSA-N
분자식
C24H44O6
평균 분자량
428.6 g/mol
단동위원소 질량
428.31378912

개요

Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. Triheptanoin was granted FDA approval on 30 June 2020.

이름 및 식별자

우선 이름
Triheptanoin
IUPAC
2,3-di(heptanoyloxy)propyl heptanoate
현지명
트라이헵타노인
영어명
TRIHEPTANOIN
분자식
C24H44O6
분자량
428.6

이름 및 동의어

Triheptanoin620-67-7TrienanthoinTrioenanthoinTriheptylinGlycerol triheptanoateHeptanoin, tri-Triheptanoic glycerideDermofeel TC 7DojolviGLYCERYL TRIHEPTANOATEglyceroltriheptanoate
이름 더 보기
트라이헵타노인트리헵타노인C7 oilTRIOENANTHINTRIHEPTANIONtri-heptanoiC7 fatty acid
2,3-di(heptanoyloxy)propyl heptanoateUX007Dub thgDermofeel tc-7Radiamuls 2375Lanol 37 ttriheptanoinatriheptanoine

데이터베이스 식별자

CAS
620-67-7
PubChem CID
69286
DTXSID
DTXSID40862306
ChEMBL
CHEMBL4297585
UNII
2P6O7CFW5K
EC Number
210-647-2
Nikkaji
J53.997J

물성

구조 계산 물성

XLogP
7.3
극성 표면적
78.9 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
6
회전 가능 결합 수
23
무거운 원자 수
30
형식 전하
0
복잡도
421

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
Cosmetics · 2건

Cosmetic ingredients (Triheptanoin) -> CIR (Cosmetic Ingredient Review)

Skin conditioning; Surfactant

Human Drugs · 2건

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

물리화학적 성질

끓는 점
200 °C · 200 °C(Press: 1 Torr)
밀도
0.966 g/mL · 0.966 g/mL at 20 °C(lit.)
굴절률
20 · n20/D 1.444
저장 조건
-20 °C, · Store at -20°C, protect from light
용해도
30 mg/ml; · DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml
물리적 상태
액체
색상
Colorless to light yellow
안정성
안정적인. 강한 산화제와 호환되지 않습니다.
화장품 원료 기능
피부 컨디셔닝 - 밀폐제점도 조절
InChI
InChI=1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 62.1% (64 of 103) of all reports.

Warning

H315 (37.9%): Causes skin irritation [Warning Skin corrosion/irritation]

P264, P273, P280, P302+P352, P321, P332+P317, P362+P364, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 103 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 3건

PMN - indicates a commenced PMN (Pre-Manufacture Notices) substance.

REACH registered substance: Propane-1,2,3-triyl trisheptanoate (EC: 210-647-2)

Triheptanoin: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesSkin Irrit. 2 (37.9%)

독성 정보

Hepatotoxicity · 1건

Serum enzyme elevations during triheptanoin therapy are frequent, mostly reflecting the underlying condition of muscle and hepatic accumulation of toxic fatty acid products and lack of adequate energy production. Elevations in CPK were present in 81%, ALT in 72% and AST in 68% of subjects treated in preregistration studies. The elevations were greater than 5 times the upper limit of normal (ULN) of CPK in 47%, ALT in 24% and AST in 15%. Nevertheless, the changes were not considered due to the triheptanoin or MCT therapy but rather to the underlying metabolic disorder and mitochondrial dysfunction. In small trials of triheptanoin in other genetic metabolic diseases, laboratory values were reported to be unchanged during supplementation. Since its approval and more widescale use, there have been no published cases of clinically apparent liver injury attributed to triheptanoin therapy, although its total clinical experience with its use has been limited.

화학 및 산업

약리 정보

ATC Code · 2건

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingTriheptanoin is approximately 80% protein bound in plasma, likely serum albumin.
Pharmacodynamics · 1건

Triheptanoin is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.

Mechanism of Action · 1건

Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.

Biological Half-LifeDue to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.
Metabolism/MetabolitesTriheptanoin is hydrolysed to heptanoate, which can be further metabolized to β-hydroxypentanoate or β-hydroxybutyrate.
FDA Pharmacological Classification · 6건

2P6O7CFW5K

TRIHEPTANOIN

Established Pharmacologic Class [EPC] - Medium-chain Triglyceride

Chemical Structure [CS] - Triglycerides

Triheptanoin is a Medium-chain Triglyceride.

TRIHEPTANOIN

Absorption, Distribution and Excretion · 3건

A single 0.3 g/kg dose of triheptanoin reaches a Cmax of 178.9 µmol/L, with a Tmax 0.5 h, and an AUC of 336.5 µmol\*h/L. A single 0.4 g/kg dose of triheptanoin reaches a Cmax of 259.1 µmol/L, with a Tmax 0.8 h, and an AUC of 569.1 µmol\*h/L.

Triheptanoin is minimally eliminated in the urine.

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
InChIKey
PJHKBYALYHRYSK-UHFFFAOYSA-N
SMILES
C(OC(=O)CCCCCC)C(OC(=O)CCCCCC)COC(=O)CCCCCC
LogP
8.86 at · 8.86 at 22℃
EPA
1 · Heptanoic acid, 1,1',1''-(1,2,3-propanetriyl) ester (620-67-7)

화학적 성질

colourless liquid

Toxicity SummarySafe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Triheptanoin

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

안전 데이터

wgk
1
tsca
TSCA listed
rtecs
MB2660000
독성
LD50 intravenous in mouse: 320mg/kg
risk_code
38
hazard_code
Xi
스토리지 클래스
11 - Combustible Solids

A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.

용도 및 제조

UsesCIR ingredient: Triheptanoin
Household ProductsInformation on 3 consumer products that contain Triheptanoin in the following categories is provided:
Use ClassificationCosmetics -> Skin conditioning; Surfactant
General Manufacturing InformationHeptanoic acid, 1,1',1''-(1,2,3-propanetriyl) ester: ACTIVE

응용 분야

용도triheptanoin is a triglyceride that acts as a surfactant and skinconditioning agent, it also helps increase product viscosity. often used in cleansers, face and neck products, moisturizers and lipsticks.